The coagulation factor VIII (FVIII) is the coagulation factor deficient in the X-chromosome-linked bleeding disorder hemophilia A. Previous transfection studies demonstrated that factor VIII was 10 -100-fold less efficiently expressed than the homologous coagulation factor, factor V. To investigate the regulatory mechanisms of FVIII synthesis and secretion, we used the yeast twohybrid system as an approach to search for proteins that associated with FVIII. The A2 domain (337-740 amino acids) of factor VIII (FVIII-A2) was used as a bait and phytanoyl-CoA ␣-hydroxylase (PAHX) was identified as a binding protein of FVIII-A2. PAHX had potential to interact with the residues 373-508 within the A2 domain, but not with A1 and A3 (the homologous domains of A2). The interaction between the A2 domain and PAHX was independent of the type 2 peroxisomal targeting signal (PTS2) of PAHX. Overexpression of PAHX in FVIII-produced cells decreased the expression of FVIII by about 70%. The elevated expression of von Willebrand factor had no effect on the suppression of FVIII secretion by PAHX. Expression of the green fluorescent PAHX fusion protein in SMMC-7721 cells affected the intracellular trafficking of FVIII-A2. These results suggested that the interaction between PAHX and FVIII-A2 was in part responsible for the low-level expression of factor VIII.
plex. Thrombin released from the complex further cleaves fibrinogen to insoluble fibrin, which stabilizes the growing clot and arrests bleeding (3) .
The gene of factor VIII is located at the tip of the long arm of the X chromosome (4) . It spans over 180 kilobases comprising 26 exons, and is one of the largest genes known. Its transcription of a 9-kilobase mRNA product may require several hours, assuming a transcription rate of 10 nucleotides per second (4) . The factor VIII gene encodes a polypeptide chain of 2351 amino acids including a signal peptide of 19 amino acids and a mature protein of 2332 amino acids. Analysis of the deduced primary structure determined from the cloned factor VIII cDNA reveals a discrete domain structure: A1-a1-A2-a2-B-a3-A3-C1-C2 (5, 6) . The A domains (A1, A2, and A3) share ϳ30% homology to each other. These domains further display a similar extent of homology to the copper-binding protein ceruloplasmin and to factor V (FV), the cofactor in the prothrombinase complex (7) . The A domains are bordered by short spacers (a1, a2, and a3) that contain clusters of Asp and Glu residues, the so-called acidic regions. The C domains are structurally related to the C domains of factor V, and share amino acid sequence similarity with the lipid-binding protein lectin discoidin I, milk fat globule protein, and a putative neuronal cell adhesion molecule from Xenopus (8 -10) . The B domain is unique in that it exhibits no significant homology with any other known proteins.
Expression of FVIII in the transfection systems is 2-3 orders of magnitude lower than that observed with other genes using similar vectors and approaches. Studies on FVIII biosynthesis and secretion have been limited by the lack of human cell lines that properly express significant amounts of factor VIII. Analysis of the factor VIII secretion process has therefore been restricted to autologous gene expression (11) . There are at least three reasons for the low level expression of FVIII: 1) FVIII mRNA is inefficiently expressed (12-15); 2) a high level of von Willebrand factor, a protein that binds and stabilizes FVIII in plasma, is required in the conditioned medium to promote stable accumulation of FVIII (12, 16) ; and 3) the primary translation product is inefficiently transported from the endoplasmic reticulum (ER) to the Golgi apparatus (17) . In contrast to FVIII, FV is efficiently transported from ER and secreted into the medium (18) . Within ER, FVIII appears to interact with a number of chaperone proteins, including calreticulin, calnexin, and the Ig-binding protein (BiP) (19 -22) . Due to the interaction with these chaperone proteins, a significant proportion of the factor VIII molecules are retained within ER, thereby limiting the transportation of FVIII to the Golgi apparatus. Recent studies indicated that this step involved an intracellular membrane lectin, endoplasmic reticulum-Golgi intermediate compartment-53 (ERGIC-53) (23) . However, the mechanism by which FVIII is synthesized and secreted has not been fully understood.
The A2 domain of FVIII (FVIII-A2) consists of ϳ330 amino acids or ϳ15% of the entire amino acid sequence of FVIII. A cluster of missense mutations within this region results in hemophilia A. Several reports indicated that the A2 domain is required for FVIII procoagulant activity. The thrombin-activated heterotrimer exhibited a pH-dependent dissociation of the A2 subunit from the complex that correlated with a loss in procoagulant activity (24) . The difference in stability between porcine and human FVIIIa correlates with the increased affinity of the porcine A2 domain compared with the human A2 domain for the A1/A3-C1-C2 heterodimer (25) . The identification of cellular proteins that do interact with FVIII, physically and/or functionally, is an approach for defining the cellular functions and regulatory mechanism of FVIII. Thus, a normal human liver cDNA library was screened by using the yeast two-hybrid system (26) with the A2 domain (337-740 aa) of FVIII as bait. PAHX (phytanoyl-CoA ␣-hydroxylase) was identified as a FVIII-associated protein via the A2 domain of FVIII, and its cellular roles in the expression and secretion of FVIII were also studied.
EXPERIMENTAL PROCEDURES
Materials-The cloning of the full-length FVIII, B domain deleted FVIII (FVIII-⌬B), and vWF cDNAs was described previously (27) . The mammalian expression vectors pcDNA3 and pcDNA3.1/myc-His(Ϫ)A were from Invitrogen (Carlsbad, CA). The expression vector pZem228 and the baby hamster kidney cells (BHK) were provided by Dr. W-F. Xu (ZymoGenetics Inc., Seattle, WA). A monoclonal antibody against the heavy chain of human factor VIII ESH5 was from American Diagnostica (Greenwich, CT). MATCHMAKER LexA two-hybrid system and human liver MATCHMAKER LexA cDNA library were products of CLONTECH (Palo Alto, CA). Protein A/G plus-agarose and a monoclonal antibody against influenza hemagglutinin (HA) were purchased from Santa Cruz Biotechnology (Santa Cruz, CA). All the restriction endonucleases and Taq polymerase were from Roche Molecular Biochemicals (Indianapolis, IN). Glutathione-Sepharose 4B beads and [ 35 S]methionine (Ͼ1000 Ci/mmol) were purchased from Amersham Pharmacia Biotech (Piscataway, NJ). Dulbecco's modified Eagle's medium, fetal bovine serum, and LipofectAMINE reagent were from Life Technologies, Inc. (Gaithersburg, MD).
Construction of the Expression Vector for FVIII-A2 (337-740 aa)-Oligonucleotide primer 1 (5Ј-GCGAATTCATGAAAAATAATGA-AGAAGCGGAA-3Ј, EcoRI site underlined) and primer 2 (5Ј-GCGTC-GACTTATCTTGGTTCAATGGCATTGTTT-3Ј, SalI site underlined) were used to generate the DNA fragment that encodes a 404-amino acid segment of FVIII (Lys 337 -Arg 740 ). The plasmid pBSK-FVIII that contains the full-length cDNA of FVIII was used as a template. The amplified cDNA for FVIII-A2 (337-740 aa) was then ligated with the pLexA vector cleaved with EcoRI and SalI.
Yeast Two-hybrid cDNA Library Screening and Protein-Protein Interaction Assay -The human liver cDNA library was constructed with the yeast plasmid pB42AD, which expresses all individual cDNAs as a fusion protein with a transcription activation domain. The expression of FVIII-A2 (337-740 aa) fused with the DNA-binding domain of LexA was screened by the reporter genes LEU2 and lacZ. The transformed yeast was grown on plates either lacking histidine to select the bait plasmid or lacking tryptophan to select the prey plasmid, respectively. The human liver cDNA library was screened as described in the manufacturer's protocol (CLONTECH). The individual cDNA of interest was purified from the positive clones and re-transformed into yeast to confirm its specific interaction with FVIII-A2 (337-740 aa). The quantitative ␤-galactosidase assay was performed on at least three independent colonies from the same clone, using o-nitrophenyl-␤-D-galactopyranoside as a substrate. Murine p53 fused with LexA as a bait and SV40 large T-antigen fused as a prey were used as a positive control. The cDNAs of interest were then sequenced using the automatic sequencer.
Construction of the A1, A3 Domains, and the Mutants of FVIII-A2 (337-740 aa)-Deletion mutagenesis was performed by the polymerase chain reaction. The mutants of FVIII-A2 were designated as A2-1 (337-581 aa), A2-2 (582-740 aa), A2-3 (373-710 aa), A2-4 (373-740 aa), A2-5 (337-710 aa), A2-6 (337-508 aa), A2-7 (373-508 aa), and A2-8 (509 -740 aa). The plasmid pSK-FVIII containing the full-length cDNA of FVIII was used as a template. A2-1 was generated from primer 1 (see above) and primer 3 (5Ј-GCGTCGACTTACTCATCAAATACAGAAAA-CA-3Ј), A2-2 from primer 4 (5Ј-GCGAATTCATGAACCGAAGCTGGT-ACCTCAC-3Ј) and primer 2 (see above), A2-3 from primer 5 (5Ј-GCG-AATTCTCAGTTGCCAAGAAGCATCC-3Ј) and primer 6 (5Ј-GCGTCG-ACTTAACTAGAAACCTTCAGTAAGG-3Ј), A2-4 from primer 5 and primer 2, A2-5 from primer 1 and primer 6, A2-6 from primer 1 and primer 7 (5Ј-GCGTCGACTTATATTTCTCCAGGCAGAATTG-3Ј), A2-7 from primer 5 and primer 7, A2-8 from primer 8 (5Ј-GCGAATTCTTC-AAATATAAATGGACAGT-3Ј) and primer 2 by polymerase chain reaction, separately. The A1 (1-336 aa) and A3 (1690 -2019 aa) domains of FVIII were amplified by primer 9 (5Ј-GCGGATCCGTGCCACCAGAG-ATACTACCT-3Ј), primer 10 (5Ј-GCGTCGACTTATCGTAGTTGGGGT-TCCTCTG-3Ј), and primer 11 (5Ј-GCGAATTCAGCTTTCAAAAGAAA-ACACG-3Ј), primer 12 (5Ј-GCGTCGACTTAATTGCTGT-ACACCAGA-AAAA-3Ј), respectively. The EcoRI site (BamHI in the case of A1) underlined in the forward primer and SalI site underlined in the reverse primer were used to clone these deletion mutants into the pLexA plasmid for interaction assay.
In Vitro Binding Analysis-The full-length cDNA of PAHX was cloned into pGEM3Z vector (Promega, Madison, WI), and its transcript was produced by an in vitro transcription kit (Promega). FVIII-A2 (337-740 aa) was cloned into the pGEX-KG vector (Amersham Pharmacia Biotech) to be expressed as a glutathione S-transferase (GST) fusion protein. The  [ 35 S]Met-labeled GST fusion protein was generated using rabbit reticulocyte lysates (Promega), and then used immediately for binding studies. The binding reactions were performed in NETN buffer (0.5% Nonidet P-40, 20 mM Tris, pH 8.0, 1 mM EDTA, 150 mM NaCl, 1 mM phenylmethylsulfonyl fluoride) at room temperature for 1 h with constant mixing. The beads were washed extensively with the same buffer, and the bound proteins were subjected to 12% SDS-PAGE analysis.
Fluorescence Imaging of Living Cells-The enhanced GFP segment (CLONTECH) was attached to the carboxyl terminus of human PAHX by standard recombinant techniques. Briefly, the DNA fragments of the full-length PAHX (1-338 aa) and the mutant of PAHX that lacks PTS2 (15-338 aa, PAHXmut) were generated by polymerase chain reaction, and then cloned into pEGFPN3 (CLONTECH) to create pEGFPN3-PAHX and pEGFPN3-PAHXmut. The FVIII-A2 domain was cloned into the pDsRed1-C1 vector (CLONTECH) so as to be expressed as a fusion with a red fluorescent protein (DsRed). The fragment of FVIII-A2 was prepared by polymerase chain reaction (5Ј-CGAATTCCATGAAAAAT-AATGAAGAAGCGGAA-3Ј and primer 2, see above), digested with EcoRI and SalI, and then ligated into the pDsRed1-C1 vector to create pDsRed1-C1-A2. SMMC-7721 hepatocellular carcinoma cells were transiently co-transfected with pDsRed1-C1-A2 and either pEGFPN3-PAHX or pEGFPN3-PAHXmut. After 72 h, cells were observed under a fluorescence microscope and digitally photographed.
Mammalian Cell Transfection-To establish a cell line that expresses FVIII, we constructed the mammalian expression vector of B domain-deleted FVIII (FVIII-⌬B). The 5.1-kilobase FVIII-⌬B fragment was recovered from the plasmid pBSK-FVIII-⌬B by XhoI and NotI digestion and inserted into pZem228 to create an expression vector pZem228-FVIII-⌬B. BHK cells were transfected with pZem228-FVIII-⌬B plasmid. A transfection mixture of 50 g/ml DNA and 30 mg/ml LipofectAMINE was applied to the cells for 5 h at 37°C in OptiMEM I (Life Technologies). The DNA-lipid complexes were replaced with complete medium for 48 h, and then the culture medium was changed into the selection medium (1 M methotrexate) for screening the expression of dihydrofolate reductase. The positive clones were picked up and grown individually to establish the stable BHK cell line that expresses FVIII-⌬B (BHK/FVIII-⌬B).
Secondary Transient Transfection of Stable Cell Lines and Their
Analyses-Once individual stable cell lines were isolated and characterized, they were used in a series of secondary transfections. PAHX and PAHXmut cDNAs were cloned into pcDNA3 to generate the expression vectors pcDNA3-PAHX and pcDNA3-PAHXmut. The cDNA fragment of wild type PAHX was cloned into the pcDNA3.1/myc-His(Ϫ)A vector to generate antisense PAHX expression vector, designated as pcDNA3.1/myc-His-antiPAHX. Various PAHX constructs (the wild type, PTS2-deleted PAHX mutant, and antisense PAHX) or the vWF expression vector were transfected into BHK/FVIII-⌬B cells for transient expression. Cells transfected with pcDNA3 or pcDNA3.1/mycHis(Ϫ)A were used as a control. The 48-h post-transfection media were collected for FVIII antigen and activity assay. At the time of harvest, cells were trypsinized and counted.
Cells were metabolically labeled at 64-h post-transfection for 2 h with [ 35 S]methionine (300 mCi/ml in methionine-free medium) (28) . The conditioned media that contained labeled proteins were harvested as described. FVIII were immunoprecipitated from the conditioned media with anti-FVIII heavy chain ESH5 and Protein A/G plus-agarose for 2 h. Immunoprecipitates were washed and resuspended in Laemmli sample buffer, and then analyzed by electrophoresis on 8% SDS-poly-acrylamide gel. The proteins were visualized by autoradiography.
Immunoprecipitation and Immunoblotting of PAHX and FVIII-⌬B-To establish a system for validating the interaction between two proteins in mammalian cells, PAHX was expressed as a HA tag fusion protein (designated as HA-PAHX). The cDNA of PAHX was cloned into pcDNA3-HA, which was derived from pcDNA3 (Invitrogen, Carlsbad, CA) by inserting a DNA fragment coding for an epitope composed of residues 2-12 (MYPYDVPDYASL) of the hemagglutinin protein from the human influenza virus. Untransfected BHK and transfected BHK/ FVIII-⌬B cell lines were used for pcDNA3-HA-PAHX transfection. Ten million cells were prepared and lysed with 100 l of Nonidet P-40 buffer (50 mM Tris-HCl, 1 mM phenylmethylsulfonyl fluoride, 150 mM NaCl, and 1% Nonidet P-40). The lysates were precleaned with Protein A/G Plus-agarose by rotating at 4°C for 30 min. The supernatant was transferred to a fresh tube. The polyclonal antibodies against human factor VIII (20 mg) used for immunoprecipitation were then added in the presence of 20 l of fresh Protein A/G Plus-agarose and incubated at 4°C for 2 h. The extract was then washed with Nonidet P-40 buffer three times. Proteins were separated on SDS-PAGE gel under the reduced condition, transferred to Hybond-ECL (Amersham Pharmacia Biotech), blocked with 2% bovine serum albumin, incubated with a monoclonal antibody against HA epitope, horseradish peroxidase-conjugated anti-mouse IgG (1:2000 diluted), and then detected using ECL detection kit (Amersham Pharmacia Biotech).
Antigen Assay of Recombinant FVIII-The sandwich enzyme-linked immunosorbent assay was used for the quantitative determination of rFVIII. The microtiter plates were first precoated with a monoclonal antibody against human FVIII. Then 5-l rFVIII standards or diluted samples were added to the wells for 2 h incubation at ambient temperature. After washing four times with PBST (phosphate-buffered saline containing 1% Triton X-100), the nonspecific binding sites were blocked by the incubation with 2% bovine serum albumin for 2 h, and the wells were washed again three times with PBST. A second monoclonal antibody (50 l of horseradish peroxidase-conjugated sheep anti-human FVIII IgG 1:2000 diluted with 0.1% bovine serum albumin) was added, and incubated at 37°C for 1 h. After washing adequately with PBST, 100 l of 0.5 mM TMB (3,3Ј,5,5Ј-tetramethylbenzidine) in 0.1 M sodium citrate, pH 4.2, was added. The enzymatic reaction was terminated by adding 50 l of 0.5 M H 2 SO 4 . The amount of the expressed antigen was quantitatively determined by reading the plate on a micro-test plate reader at a wavelength of 450 nm. The standard curve was constructed by plotting the mean absorbance value calculated for each rFVIII standard versus its corresponding concentration.
Procoagulant Activity Assay of FVIII-FVIII procoagulant activity, which was defined as the activity that corrects the clotting defect of plasma from hemophilia A patients, was measured by the one-stage method using the congenitally FVIII-deficient plasma as the substrate. One unit corresponded to 200 ng/ml (100%) and the sensitivity of the assay was about 20 -30 milliunits/ml. The physiologic FVIII concentrations were defined as 100 -200 ng/ml (29) .
RESULTS

Identification of the FVIII A2 Domain-associated Protein
PAHX-The fusion protein of the FVIII-A2 domain (337-740 aa) and the LexA DNA-binding domain was used as a bait to screen a human fetal liver cell cDNA library in the yeast two-hybrid system. Yeast strain EGY48, containing the two LexA responsive reporter genes, His and lacZ, was used for the library screening. Two positive cDNA clones were identified: one was the full-length cDNA of human PAHX, the other was a truncated form of PAHX (PAHXmut, 15-338 aa) that lacks the PTS2 motif which has the consensus sequence RLX 5 (H/Q)L prerequisite to direct protein into the peroxisomes (30, 31) . The results demonstrated that PAHX was able to form a specific complex with the A2 domain of FVIII and the interaction was independent of the PTS2 signal.
The Specific Binding Site within the FVIII-A2 Domain for PAHX-Additional studies were performed to determine the specific binding site within the FVIII-A2 domain for PAHX. The deletion mutants of A2 domain were constructed as described under "Experimental Procedures" and cloned into the BD fusion vector pLexA (Fig. 1) . The A1 and A3 domains and A2 domain mutants were co-transfected into yeast EGY48 strain with either PAHX or PAHXmut. ␤-Galactosidase activ- ities were measured to determinate the interaction (Fig. 2) . The result showed that PAHX or PAHXmut could interact specifically with the FVIII-A2 domain but not with either A1 or A3 domain. The PAHX-binding site within the FVIII-A2 domain was located in residues 373-508, which comprised the binding site for FIXa and LRP (32) .
Interaction between PAHX and the FVIII-A2 Domain in Vitro-To demonstrate the interaction of PAHX and the FVIII-A2 domain in vitro, we constructed the expression vector for the fusion protein of FVIII-A2 and GST (GST-A2
). The [ 35 S]Met-labeled GST-A2, GST mock fusion proteins, and PAHX were generated separately using an in vitro translation system. One-third of the reaction mixture was loaded onto SDS-PAGE (Fig. 3, lanes 2, 3, and 5) , and one-third of labeled PAHX was incubated with equal amounts of either GST-A2 or GST-mock, and then subjected to glutathione bead binding assay for the GST epitope. The beads were washed, and the bound polypeptides were analyzed on SDS-PAGE. The GST-A2 fusion protein did pull down PAHX (Fig. 3, lane 1) , while the GST-mock protein did not (Fig. 3, lane 4) . Quantification of protein immobilized on bead was about 50% (GST-A2), 24% (PAHX), and 25% (GST-mock) using video densitometry. Thereby demonstrating not only that A2 and PAHX interacted specifically but also that the interaction was direct, not involving an intermediary molecule.
PAHX Binds FVIII-⌬B in Vivo-To determine whether PAHX interacts with FVIII-⌬B in vivo, the HA-PAHX fusion protein was expressed in BHK or BHK/FVIII-⌬B cell lines. The expression of PAHX was confirmed by a monoclonal antibody against HA epitope (Fig. 4) . FVIII-⌬B was immunoprecipitated, and analyzed using Western blot with an anti-HA monoclonal antibody. A 39-kDa PAHX was co-immunoprecipitated from BHK/FVIII-⌬B cells (Fig. 4) . Under the same condition, no PAHX was co-immunoprecipitated in the wide type BHK cells (Fig. 4) . These results further verified that PAHX did associate with FVIII-⌬B in vivo.
The Effect of PAHX on the Intracellular Distribution of the FVIII-A2 Domain-To analyze the role of PAHX in the FVIII secretory pathway, we co-transfected the SMMC-7721 hepatocellular carcinoma cells with pDsRed1-C1-A2 and either pEG-FPN3-PAHX or pEGFPN3-PAHXmut. These experiments were performed to address whether the synthesis of PAHX affected the intracellular trafficking of the FVIII-A2 domain. When these transfected cells were analyzed by the dual fluorescence imaging of fusion proteins, the appearance of the subcellular FVIII-A2 was shifted from whole cell into a pattern of deposition staining. The change was clearly visible in the red-only projection images when the PAHX (pEGFPN3-PAHX) and FVIII-A2 (pDsRed1-C1-A2) co-transfected cells were compared with the FVIII-A2 only cells (Fig. 5, D versus G) . Merging the separate projection images obtained from green-only (Fig. 5E ) and red-only (Fig. 5D ) emission detection, we observed that the double-transfected cells contained yellow granules indicating co-localized compartmental storage of FVIII-A2 and PAHX (Fig. 5F ). The overexpression of PAHX mutant lacking PTS2 did not change the distribution of FVIII-A2 (Fig. 5, A versus G) . It could be concluded that the transient co-transfection of PAHX and FVIII-A2 caused a significant change of the intracellular distribution of the FVIII-A2 domain, and the effect of PAHX was dependent on its peroxisomal targeting signal PTS2.
The Effect of PAHX on the Expression of FVIII-⌬B-The stable BHK/FVIII-⌬B cells line were used for the transient expression of PAHX. Vector pcDNA3 or pcDNA3.1/mycHis(Ϫ)A was used as a control. The culture supernatant was collected, and the expression and activity of rFVIII-⌬B were assayed. The activity as well as the expression of FVIII-⌬B were decreased gradually to 30% when the expression of PAHX was increased (Fig. 6A) . The PAHXmut had no effect on the expression of FVIII-⌬B, which suggested that the inhibition of FVIII-⌬B expression by PAHX was dependent on the peroxisomal targeting signal. The expression of FVIII-⌬B was increased to 130% when the expression of PAHX was inhibited by antisense PAHX.
In the plasma, Factor VIII is tightly associated with vWF, its physiological carrier protein (33) . The importance of complex formation between Factor VIII and vWF was exemplified by patients having severe von Willebrand disease (type 3), who were in short of vWF protein. Apart from exhibiting a defect in primary hemostasis due to the absence of vWF, these patients also have a secondary deficiency of Factor VIII. In our study, the expression of vWF with FVIII-⌬B obviously facilitated the gene expression as expected (Fig. 6B) (12, 27) . The activity of FVIII in vWF-transfected cells was decreased to 41.6% when PAHX were co-transfected. The effect of PAHX on the expression of FVIII in BHK cells transfected with vWF was similar to those untransfected with vWF. The results showed that vWF was not involved in the suppression of the FVIII expression by PAHX. Metabolic pulse labeling was performed to characterize whether the decreased activity of FVIII-⌬B correlated with its decreased secretion. Analysis of the pulse-labeled conditioned media demonstrated that the amount of FVIII-⌬B secreted into the conditioned media was suppressed by the expression of PAHX (Fig. 7) . DISCUSSION The concentration of FVIII in plasma is quite low, ranging from 100 to 200 ng/ml (34) . The low level expression of the transfected FVIII gene was ascribed to the low level production of FVIII mRNA (34) and the inefficient secretion of FVIII protein due to its interaction with the protein chaperone, BiP/ GRP78 (19, 35) . These effects can be circumvented by using a B domain-deleted FVIII gene, which results in a marked increase in FVIII synthesis (30, 43) ing patients with hemophilia A. FVIII-⌬B is also a preferred molecule for the gene therapy approach because of its higher expression level. For these reasons we used FVIII-⌬B in our studies and postulated that FVIII-⌬B would traffic intracellularly in a manner analogous to the full-length FVIII.
The human protein PAHX is a peroxisomal enzyme catalyzing the first step in phytanic acid oxidation: the ␣-oxidation of phytanoyl-CoA to ␣-hydroxyphytanoyl-CoA. This enzyme is targeted to peroxisome by the protein PEX7, the receptor for the type 2 peroxisomal targeting signal (PTS2), an aminoterminal motif with the consensus sequence of RLX 5 (H/Q)L, which is prerequisite to direct proteins into the peroxisome (30, 31, 36) . The defect of PAHX results in Refsum disease, a peroxisomal disorder characterized by the accumulation of the fatty acid such as phytanic acid.
Tissue expression of FVIII has also been studied through organ and tissue transplantation, which demonstrates that in human and dog FVIII is produced in the liver, spleen, and lymph nodes (37) (38) (39) (40) (41) . The mRNA for PAHX, however, has been found in specific tissues such as liver and kidney, but not in spleen, brain, heart, lung, and skeletal muscle (42) . These results provide the possibility that FVIII and PAHX interact with each other in tissues such as liver.
The physiological significance of the interaction between PAHX and FVIII remains to be elucidated. Interestingly, the cleavable PTS2 signal located at the NH 2 -terminal part of PAHX is not required for PAHX to interact with FVIII, thus the FVIII binding is unlikely involved in the recognition of the signal specific for the PTS2 receptor (PEX7). However, like other mitochondrial proteins, peroxisomal proteins are synthesized in cytoplasmic ribosome and post-translationally imported into the organelle by a process that requires Hsp70 class cytoplasmic chaperones. Intracellular FVIII is detected in association with chaperone calnexin maximally within 30 min to 1 h following synthesis, whereas FV cannot be detected in association with calnexin. In contrast, both FVIII and FV interact with calreticulin during the transition through the secretory pathway. Calnexin and calreticulin preferentially interact with glycoproteins containing monoglucosylated N-linked oligosaccharides and are supposed to transport proteins through the secretory pathway. The interaction between FVIII and these protein chaperones seems to be dependent on the B domain of FVIII (22) . So it would be of interest to investigate whether FVIII provides the platform for PAHX to interact with cytoplasmic chaperones.
Although most evidence supports that FVIII is expressed at least in hepatocytes (34, 40, 43, 44) , the major physiological source for the in vivo expression of FVIII is still unknown. Whereas HepG2 cells are known to express FV (45) , there are no known established or primary cell lines that express FVIII. Thus, our knowledge of FVIII biosynthesis is mostly derived from the expression of the FVIII cDNA in transfected mammalian cells. It is interesting to note that the inhibition of PAHX expression improves the secretion of FVIII by only 30% (Fig. 6) , and the endogenetic PAHX does not change the intracellular expression of FVIII in the deposition staining pattern (Fig. 5 ). Considering the low-level expression of FVIII in vivo, the effect of PAHX may be taken into more account in the regulation of FVIII synthesis or secretion. Whether or not PAHX is involved in these processes is currently under investigation. Irrespective thereof, our data indicated that the secretion of FVIII into the culture medium was decreased by PAHX. Additional studies on their binding affinity and their physiological concentration in the normal and disease conditions are required for the better understanding of the biological function of this interaction.
Recently, it has been reported that PAHX is deficient in three peroxisomal neurologic disorders: Zellweger syndrome, rhizomelic chondrodysplasia punctata, and Refsum disease (46) , all result from the accumulation of phytanic acid in tissues and plasma (47) (48) (49) . It has also been reported that PAHX interacts with the FKBP12-like domain of FKBP52 in the presence of FK506. Thus, PAHX is potentially involved in the cellular signal transmission by FKBP52 in the presence of FK506, in a manner comparable to the calcineurin-FKBP12 complex (50) . The diversity of PAHX function in these reports suggests that the physiological role of PAHX has not been fully understood. Our results indicated that the overexpression of PAHX in FVIII-⌬B produced cells not only decreased the FVIII secretion into the culture media, but also changed the intracellular distribution of FVIII-A2. FVIII is synthesized in cells and secrete into the plasma to be a member of coagulation cascade. PAHX is a peroxisomal protein, which should be targeted into peroxisome by the PTS2 signal. The interaction between PAHX and FVIII is independent of PTS2, but the effect of PAHX on FVIII expression is dependent on PTS2. The function of PAHX demonstrated in this report is somewhat like protein chaperones, BiP and calnexin, which regulate the secretion of FVIII (22) . It is speculated that PAHX functions as a protein chaperone, interacting with the A2 domain of FVIII and retarding FVIII in the secretory pathway. Thus, the amount of FVIII is decreased in the culture medium.
In conclusion, PAHX is another specific binding protein for human coagulation factor VIII. Overexpression of PAHX changes the intracellular distribution of FVIII-A2 and decreases the expression of FVIII. However, it is still too early to conclude that this physical interaction is important to the physiological effect of FVIII in vivo. Further studies on this newly identified FVIII-associated protein are required for a better understanding of its physiological role.
